317 filings
8-K
LSTA
Lisata Therapeutics Inc
17 Apr 24
Departure of Directors or Certain Officers
4:04pm
8-K
LSTA
Lisata Therapeutics Inc
29 Feb 24
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
4:09pm
8-K
LSTA
Lisata Therapeutics Inc
2 Nov 23
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
LSTA
Lisata Therapeutics Inc
14 Aug 23
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
LSTA
Lisata Therapeutics Inc
11 Jul 23
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
4:01pm
8-K
43wlfx 6z2a2kg9
14 Jun 23
Submission of Matters to a Vote of Security Holders
5:05pm
8-K
vzr2g63e5pwe6npwt
9 May 23
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
ra10r2ko6uswvjoik4
1 May 23
Departure of Directors or Certain Officers
4:01pm
8-K
92exw2ntoku2ld
30 Mar 23
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:07pm
8-K
sxwfa02
6 Feb 23
Results of Operations and Financial Condition
4:02pm
8-K
8i4qkg7rl
10 Nov 22
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4:10pm
8-K/A
26t7t 50kdxe
14 Oct 22
Financial Statements and Exhibits
4:01pm
8-K/A
vbut5m3
4 Oct 22
Other Events
4:42pm
8-K
r59oltyev13g01b8
29 Sep 22
Other Events
4:01pm
8-K
ytqv11pd 6nsf821
22 Sep 22
Regulation FD Disclosure
4:02pm
8-K
fpj1p
15 Sep 22
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
9:16am
8-K
2iq3zz 3ri8j02
14 Sep 22
Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics
5:01pm
8-K
1wl0gf n2xng7yct9l
19 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:33pm
8-K
ypfle2pqahzlh4b
5 Aug 22
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
4:01pm
8-K
82fi3axoth8uonhm87a
23 May 22
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
4:08pm